Invest in Women. Invest in Communities

For smallholder families, livestock mean income, food, school fees, and independence. When women have access to healthy animals, veterinary care, vaccines, and markets, they gain earnings and decision-making power.

Investing in women livestock producers strengthens food systems, reduces poverty, and builds resilient rural economies — because when women thrive, communities prosper.

Year in Review: GALVmed 2025

We’re excited to share GALVmed’s 2025 Year in Review, an overview of our accomplishments and the progress made throughout the year in advancing our mission.

The review reflects a year of meaningful impact and our continued commitment to strengthening livelihoods through improved livestock health.

Read it here.

Unlocking Africa’s $4bn livestock opportunity

GALVmed CEO Dr Lois Muraguri highlights how harmonised regulation will help ensure that safe and effective veterinary medicines and products reach the people who need them most, while also making the market more predictable for both manufacturers and regulators.

The proposed Pan-African Regulatory Authorities Network for Veterinary Products (PARAN-VPs) will guide continental cooperation on veterinary product regulation. It will serve as a continental platform for regulatory cooperation, helping countries align standards, share information and strengthen oversight of veterinary medicines.

Our Vision

Transformational improvement in the well-being and economic progression of small-scale livestock producers.

Our Mission

We will contribute to the transformation of small-scale livestock producers’ lives by:

  • understanding the constraints to animal health and how to overcome them;
  • engaging the animal health industry; and
  • ensuring awareness, availability and adoption of effective animal health interventions.

•	Approximately 8.6 million cumulative annual customers over the period 2014 to 2025, before adjustment for potential repeat customers
•	Approximately US$157.9 million in poultry deaths averted, from 2014 to 2025
•	3.89 billion doses of livestock vaccines, therapeutics and other animal health products sold to small-scale producers across Africa and South Asia from 2014 to 2025
•	16 products taken to full development since 2010 
•	24 products registered to date under the Mutual Recognition Procedure
•	US$583.2 million in total net economic benefits to SSPs from the sale of vaccines and animal health products. Of this, US$260.1 million represents additional net economic benefit generated through GALVmed’s efforts to expand market availability and catalyse new adoption.

Our work

Product development

GALVmed specialises in product development partnerships uniquely established to translate global research progress into tangible livestock disease control tools for the developing world.

Commercial development

Our work with our partners supports the small-scale livestock producers of the world.

Enabling environment

An enabling environment that allows for the successful translation of research products to sustainable animal health solutions for small scale livestock producers is essential to achieving GALVmed’s mission.

Blog

Why gender-intentional programmes are key to livestock systems development

Applying a gender lens to livestock programmes is not an optional add-on, but a strategic necessity. VITAL 2 is a gender-intentional investment, designed to ensure that gender-related barriers and norms are identified and addressed so that women are not excluded from the benefits of ruminant vaccination as markets and delivery systems expand.

Showcasing Impact: GALVmed Key Achievements

Over the years, GALVmed through its partners, has implemented impactful programmes across Africa and South Asia, leading to significant achievements.

The EAC Mutual Recognition Procedure expands its scope 

The MRP has expanded its scope to include ectoparasiticides, aquatic animal medicines, and animal nutritional supplements—broadening its impact and strengthening its relevance across both livestock and aquaculture sectors. 

Voices from the field

Why gender-intentional programmes are key to livestock systems development

Applying a gender lens to livestock programmes is not an optional add-on, but a strategic necessity. VITAL 2 is a gender-intentional investment, designed to ensure that gender-related barriers and norms are identified and addressed so that women are not excluded from the benefits of ruminant vaccination as markets and delivery systems expand.

Showcasing Impact: GALVmed Key Achievements

Over the years, GALVmed through its partners, has implemented impactful programmes across Africa and South Asia, leading to significant achievements.

To truly beat sleeping sickness we need to treat animals too

If Africa can mobilise the investments needed to eliminate sleeping sickness in people, it can and must show the same commitment to protecting the animals that sustain its economy.

Stopping the spread of Peste des Petits Ruminants (PPR) starts with vaccine access in Africa

Imagine that over the course of 10 days, 80 per cent of your livelihood is destroyed. This is a reality for millions of small-scale producers in Africa who depend on sheep and goats for income, nutrition and survival, but have to contend with Peste des Petits Ruminants (PPR), a highly contagious disease with a mortality rate of up to 90 per cent.

The cost of livestock diseases and how vaccination makes a difference

Each year, 20% of livestock production is lost to disease. Vaccination is a vital tool in controlling disease outbreaks and preventing devastating losses.

Read more Voices from the field articles…